JP2016507066A - 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 - Google Patents

多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 Download PDF

Info

Publication number
JP2016507066A
JP2016507066A JP2015557128A JP2015557128A JP2016507066A JP 2016507066 A JP2016507066 A JP 2016507066A JP 2015557128 A JP2015557128 A JP 2015557128A JP 2015557128 A JP2015557128 A JP 2015557128A JP 2016507066 A JP2016507066 A JP 2016507066A
Authority
JP
Japan
Prior art keywords
fragment
biological sample
bcma
subject
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015557128A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507066A5 (enExample
Inventor
ジェイムズ アール． ベレンソン，
ジェイムズ アール． ベレンソン，
ハイミン チェン，
ハイミン チェン，
エリック サンチェス，
エリック サンチェス，
Original Assignee
インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ
インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ, インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ filed Critical インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ
Publication of JP2016507066A publication Critical patent/JP2016507066A/ja
Publication of JP2016507066A5 publication Critical patent/JP2016507066A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • G01N33/57505—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G01N33/57557—
    • G01N33/57585—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2015557128A 2013-02-08 2014-02-07 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 Withdrawn JP2016507066A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361762753P 2013-02-08 2013-02-08
US61/762,753 2013-02-08
PCT/US2014/015338 WO2014124280A1 (en) 2013-02-08 2014-02-07 Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018090456A Division JP2018136344A (ja) 2013-02-08 2018-05-09 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法

Publications (2)

Publication Number Publication Date
JP2016507066A true JP2016507066A (ja) 2016-03-07
JP2016507066A5 JP2016507066A5 (enExample) 2017-03-09

Family

ID=51300158

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015557128A Withdrawn JP2016507066A (ja) 2013-02-08 2014-02-07 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法
JP2018090456A Pending JP2018136344A (ja) 2013-02-08 2018-05-09 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018090456A Pending JP2018136344A (ja) 2013-02-08 2018-05-09 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法

Country Status (5)

Country Link
US (2) US10126301B2 (enExample)
EP (1) EP2954330A4 (enExample)
JP (2) JP2016507066A (enExample)
CA (1) CA2900529A1 (enExample)
WO (1) WO2014124280A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016507066A (ja) 2013-02-08 2016-03-07 インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法
US11353458B2 (en) 2015-10-30 2022-06-07 Glaxosmithkline Intellectual Property Development Limited Prognostic method
EP3402515B8 (en) 2016-01-12 2021-12-08 Oncotracker, Inc. Improved methods for monitoring immune status of a subject
US20200326339A1 (en) 2016-05-16 2020-10-15 James Richard BERENSON Improved methods for monitoring immune status of a subject
KR20190116420A (ko) 2017-02-17 2019-10-14 프레드 헛친슨 켄서 리서치 센터 Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법
US20230059544A1 (en) * 2017-02-28 2023-02-23 Menarini Silicon Biosystems, S.p.A. Kits and assays to detect circulating multiple myeloma cells from blood
EP3639028B1 (en) 2017-06-13 2025-10-15 Onco Tracker, Inc. Diagnostic, prognostic, and monitoring methods for breast cancer
ES2644580B2 (es) * 2017-07-26 2018-06-04 Universitat Politècnica De València Procedimiento de diagnóstico de lupus eritematoso sistémico (les)
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CN111886012A (zh) 2017-11-06 2020-11-03 朱诺治疗学股份有限公司 细胞疗法与γ分泌酶抑制剂的组合
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3098420A1 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
JP7577647B2 (ja) * 2018-08-31 2024-11-05 エフ． ホフマン－ラ ロシュ アーゲー Ｄｌｂｃｌについての予後指標におけるチミジンキナーゼ（ｔｋ－１）
CN114026122B (zh) 2019-02-21 2024-12-31 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
CR20210576A (es) 2019-05-21 2021-12-15 Novartis Ag Moléculas de unión a cd19 y usos de las mismas
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
BR112023020832A2 (pt) 2021-04-08 2023-12-19 Marengo Therapeutics Inc Moléculas multifuncionais ligadas a tcr e seus usos
CN117305458B (zh) * 2023-10-20 2024-06-21 四川省医学科学院·四川省人民医院 TKTmRNA检测试剂在制备多发性骨髓瘤筛查试剂盒中的用途及试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207474A1 (en) * 2005-11-01 2007-09-06 Ansell Stephen M PROMOTER POLYMORPHISMS OF THE BLyS GENE AND USE IN DIAGNOSTIC METHODS
WO2012143498A1 (en) * 2011-04-21 2012-10-26 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
WO2012163805A1 (en) * 2011-05-27 2012-12-06 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
DE69733694T2 (de) 1996-07-10 2006-07-06 Muramatsu, Takashi, Nagoya Verwendung von proteinen aus der mk familie als hämatopoietischer faktor
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US20040002068A1 (en) * 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2002306596B2 (en) 2001-02-27 2008-01-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
CA2459890A1 (en) 2001-09-06 2003-03-20 Biogen Idec Ma Inc. Crystal structure of baff, and use thereof in drug design
CA2523776A1 (en) 2003-03-07 2004-09-23 Xencor, Inc. Baff mutants with at least one amino acid substitution and methods of their production
WO2006025345A1 (ja) 2004-08-31 2006-03-09 Kowa Company, Ltd. 抗ヒトｂａｆｆ抗体
EP1814577B1 (en) 2004-10-13 2014-04-23 The Washington University Use of baff to treat sepsis
JP2008525002A (ja) 2004-12-23 2008-07-17 ラボラトワール セローノ ソシエテ アノニム Ｂｃｍａポリペプチド及びその使用
WO2007039489A1 (en) * 2005-09-26 2007-04-12 Apotech Corporation Antibodies against april as biomarkers for early prognosis of lymphoma patients
WO2007056288A2 (en) * 2005-11-08 2007-05-18 Biogen Idec Ma Inc. Methods of evaluating baff
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
SI1966202T1 (sl) 2005-12-13 2012-01-31 Incyte Corp S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze
US20080058316A1 (en) 2006-02-27 2008-03-06 The Johns Hopkins University Cancer treatment with gama-secretase inhibitors
PT2016102E (pt) 2006-05-03 2012-05-15 Us Gov Health & Human Serv Recetores de célula t quimérica e materiais relacionados e métodos de uso
EP2173752B2 (en) 2007-06-13 2022-07-13 Incyte Holdings Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
JP5739326B2 (ja) 2008-04-25 2015-06-24 ザイモジェネティクス， インコーポレイテッド Ｂ細胞上でのｂｃｍａタンパク発現レベル及び診断法における使用
DK2406284T5 (en) 2009-03-10 2017-06-12 Biogen Ma Inc ANTI-BCMA ANTIBODIES
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
EP2914628A1 (en) 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
JP2016507066A (ja) 2013-02-08 2016-03-07 インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法
JP2017503001A (ja) 2014-01-20 2017-01-26 ギリアード サイエンシーズ， インコーポレイテッド がんを処置するための療法
US10144782B2 (en) 2014-04-30 2018-12-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Humanized antibodies against CD269 (BCMA)
US10363260B2 (en) 2014-05-28 2019-07-30 Oncotracker, Inc. Anti-cancer effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids
WO2015191668A1 (en) 2014-06-10 2015-12-17 Institute For Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
SMT202200285T1 (it) 2014-08-11 2022-09-14 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk, un inibitore di pd-1 e/o un inibitore di pd-l1
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
JP6997620B2 (ja) 2014-12-05 2022-02-04 メモリアル スローン ケタリング キャンサー センター Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用
US11060150B2 (en) 2015-03-17 2021-07-13 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating cancer
EP3662909A1 (en) 2015-07-24 2020-06-10 Oncotracker, Inc. Gamma secretase modulators for the treatment of immune system dysfunction
JO3799B1 (ar) 2015-08-17 2021-01-31 Janssen Pharmaceutica Nv الأجسام المضادة ل bcma، جزيئات ربط الانتيجين ثنائية التحديد التي تربط bcma و cd3، و استخداماتها
US11353458B2 (en) 2015-10-30 2022-06-07 Glaxosmithkline Intellectual Property Development Limited Prognostic method
EP3402515B8 (en) 2016-01-12 2021-12-08 Oncotracker, Inc. Improved methods for monitoring immune status of a subject
US20200326339A1 (en) 2016-05-16 2020-10-15 James Richard BERENSON Improved methods for monitoring immune status of a subject
EP3490590A2 (en) 2016-08-01 2019-06-05 Novartis AG Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
WO2018085363A2 (en) 2016-11-02 2018-05-11 Berenson James Richard Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma
EP3639028B1 (en) 2017-06-13 2025-10-15 Onco Tracker, Inc. Diagnostic, prognostic, and monitoring methods for breast cancer
JP2020528885A (ja) 2017-07-19 2020-10-01 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
WO2020092792A2 (en) 2018-10-31 2020-05-07 Oncotracker, Inc. Method of enhancing immune-based therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207474A1 (en) * 2005-11-01 2007-09-06 Ansell Stephen M PROMOTER POLYMORPHISMS OF THE BLyS GENE AND USE IN DIAGNOSTIC METHODS
WO2012143498A1 (en) * 2011-04-21 2012-10-26 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
WO2012163805A1 (en) * 2011-05-27 2012-12-06 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERIC SANCHEZ,ET AL.: "Serum B-cell maturation antigen is elevated in multiole myeloma and correlates with disease status a", BRITISH JOURNAL OF HAEMATOLOGY, vol. Volume 158, Issue 6, JPN7017003662, 18 July 2012 (2012-07-18), pages 727 - 738, ISSN: 0003679709 *
JEROME MOREAUX,ET AL.: "BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamet", BLOOD, vol. VOLUME 103,NUMBER 8, JPN7017003663, 15 April 2004 (2004-04-15), pages 3147 - 3157, ISSN: 0003679710 *

Also Published As

Publication number Publication date
EP2954330A4 (en) 2016-08-31
CA2900529A1 (en) 2014-08-14
US20160131654A1 (en) 2016-05-12
EP2954330A1 (en) 2015-12-16
US20190107541A1 (en) 2019-04-11
WO2014124280A1 (en) 2014-08-14
US12174189B2 (en) 2024-12-24
US10126301B2 (en) 2018-11-13
JP2018136344A (ja) 2018-08-30

Similar Documents

Publication Publication Date Title
US12174189B2 (en) Diagnostic, prognostic, and monitoring methods for chronic lymphocytic leukemia
JP2022058619A (ja) 被験体の免疫状態をモニタリングするための改善された方法
EP3458853B1 (en) Improved methods for monitoring immune status of a subject
EP3639028B1 (en) Diagnostic, prognostic, and monitoring methods for breast cancer
EP2551673B1 (en) Methods for the detection of cancer infiltration of the central nervous system
ES2939143T3 (es) Biomarcadores para una politerapia que comprende lenvatinib y everolimus
WO2018085363A2 (en) Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma
HK40082699A (en) Improved methods for monitoring immune status of a subject
CA3010019C (en) Improved methods for monitoring immune status of a subject
EP3832309A1 (en) Composition for diagnosis of bone metastasis of cancer and kit comprising same
HK40000182B (en) Improved methods for monitoring immune status of a subject
HK40007456B (en) Improved methods for monitoring immune status of a subject
HK40007456A (en) Improved methods for monitoring immune status of a subject
KR101567053B1 (ko) 방사선 피폭에 의한 간 손상 예측용 바이오마커 및 그 예측방법
US20090226933A1 (en) Quantification of fusion proteins and their activity from chromosomal translocation
JP6195716B2 (ja) 抗癌剤耐性診断マーカー
WO2025121385A1 (ja) Ｔ細胞関連疾患の病態、予後及び治療効果の予測技術
WO2010062705A1 (en) Cancer diagnosis using ki-67
KR20180099722A (ko) 예측 방법 및 상기 방법에 유용한 키트

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180405

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180809